1. Evaluation of high-risk human papillomavirus testing and anal cytology to detect high-grade anal intraepithelial neoplasia
- Author
-
Petra M. Casey, Paula D.M. Chantigian, Matthew J. Binnicker, Aimee C. Boerger, Sarah M. Jenkins, Amy A. Swanson, Michael R. Henry, Christopher P. Hartley, and Margaret E. Long
- Subjects
Adult ,Male ,medicine.medical_specialty ,Genotype ,Biopsy ,Population ,Anal Canal ,030209 endocrinology & metabolism ,Alphapapillomavirus ,Real-Time Polymerase Chain Reaction ,Sensitivity and Specificity ,Gastroenterology ,Pathology and Forensic Medicine ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Cytology ,Internal medicine ,medicine ,Humans ,Mass Screening ,Human papillomavirus ,education ,Early Detection of Cancer ,Aged ,Aged, 80 and over ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,Anal intraepithelial neoplasia ,Positive Cytology ,Anal biopsy ,Middle Aged ,Anus Neoplasms ,Anal cytology ,Molecular Diagnostic Techniques ,030220 oncology & carcinogenesis ,Female ,business ,Carcinoma in Situ - Abstract
Introduction Optimal screening for detection of anal precancer has not been established, and most studies involve very high-risk populations. We evaluated high-risk human papillomavirus (HPV) testing and anal cytology to detect high-grade anal intraepithelial neoplasia ( > AIN2) in a cohort with mostly moderate risk factors for AIN. Materials and Methods Patients > 35-years-old undergoing anal biopsy for various lesions received HPV testing by Roche cobas and a subset by Hologic APTIMA HPV assays with concurrent anal ThinPrep cytology. Biopsies were blindly reviewed by 3 authors, and consensus diagnosis was compared with HPV and cytology results. Sensitivity and specificity for > AIN2 detection by HPV testing and cytology ( > ASC-US) were calculated. Results Among 64 patients, 19 (29.7%) showed > AIN2 on biopsy. All patients were tested by cobas, and 35 (54.7%) were positive. A subset of 39 patients were also tested by APTIMA, and 18 (46.2%) were positive. Positive cytology ( > ASC-US) was present in 37 (57.8%) patients, with 27 (73.0%) of these positive by cobas. HPV testing alone yielded 75.0% and 84.2% sensitivity for APTIMA and cobas, respectively; specificity was 66.7% and 57.8%. Sensitivity and specificity of cytology alone was 78.9% and 51.1%. Combined HPV testing and cytology had a sensitivity and specificity of 91.7% and 37.0% for APTIMA and 94.7% and 40.0% for cobas. Conclusions Combined HPV testing and cytology had the highest sensitivity for > AIN2 detection, with a performance comparable to cervical cancer screening tests, suggesting this strategy may represent a viable screening option in a population with moderate risk factors for AIN.
- Published
- 2021
- Full Text
- View/download PDF